Giuseppe Saglio, MD of the University of Turin, Turin, Italy discusses the future of chronic myeloid leukemia (CML) treatment. According to Prof Saglio, for a specific group of patients, the future will be a real cure. This may only be achievable in 10-15% of patients even with imatinib treatment. With 2nd generation tyrosine kinase inhibitors (TKI), this may be improved to 30-35%.. There are, however, patients that cannot receive TKI treatment. Prof Saglio discusses the need to find the best combination therapy, which may be beneficial for all patients. Recorded at the 2016 Annual Meeting of the British Society of Haematology (BSH) and International Society of Hematology (ISH), held in Glasgow, Scotland.